Quest Diagnostics Inc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Quest Diagnostics Inc (DGX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of 0.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-02-26
- Quest Diagnostics Inc effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was 0.50%, a 50.00% decline from fiscal 2024.
- Quest Diagnostics Inc effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was 1.00%, a 11.11% increase from fiscal 2023.
- Quest Diagnostics Inc effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2023 was 0.90%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month |
|---|---|
| 2025-12-31 | 0.50% 10-K · filed 2026-02-26 |
| 2024-12-31 | 1.00% 10-K · filed 2026-02-26 |
| 2023-12-31 | 0.90% 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |